AOA Dx is at the forefront of developing a novel frontier in early-stage cancer detection for women, utilizing the power of glycolipids and their proprietary biomarker technology. Their GlycoLocate platform targets tumor marker gangliosides, advancing early cancer detection while addressing a critical need by developing AKRIVIS GD, a liquid biopsy test designed for early-stage detection of ovarian cancer.

Over the past 12-18 months, AOA Dx has achieved significant milestones, signaling their rapid progress and growing impact:

-Raised $17M bringing total to $24M raised 

-Published paper in prestigious journal Frontiers of Oncology 

-Opened up US HQ in Denver, Colorado

-Started clinical trial 

Behind AOA Dx's success lies a robust network of support and guidance. The Eddies and Mass Innovation Network has offered access to diverse advisors, fellow founders, and industry connections, fostering collaboration, sharing insights, and facilitating vital introductions.